TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1-NF-kappa B and - AP-1 pathways | |
Zhao, Peiqing[1]; Wang, Sujie[2]; Jiang, Jie[3]; Liu, Hong[4]; Zhu, Xiaolan[5]; Zhao, Ning[6]; Li, Jigang[7]; Yin, Yingchun[8]; Pan, Xiaoyan[9]; Yang, Xiuzhen[10] | |
刊名 | MOLECULAR IMMUNOLOGY
![]() |
2018 | |
卷号 | 101页码:471-478 |
关键词 | TIPE2 Osteosarcoma MDR1 Cis-platin TAK1 |
ISSN号 | 0161-5890 |
DOI | http://dx.doi.org/10.1016/j.molimm.2018.08.010 |
URL标识 | 查看原文 |
收录类别 | SCI(E) ; PUBMED |
WOS记录号 | WOS:000446283700054 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/5333460 |
专题 | 江苏大学 |
作者单位 | 1.[1]Jiangsu Univ, Affiliated Hosp 4, Dept Gynecol Oncol, Zhenjiang, Jiangsu, Peoples R China. 2.Zibo Cent Hosp, Ctr Translat Med, Zibo, Peoples R China. 3.[2]Zibo Cent Hosp, Dept Oncol, Zibo, Peoples R China. 4.[3]Binzhou Med Univ, Yantai Affiliated Hosp, Dept Clin Lab, Yantai, Peoples R China. 5.[4]Zibo Cent Hosp, Ctr Translat Med, Zibo, Peoples R China. 6.[5]Jiangsu Univ, Affiliated Hosp 4, Dept Gynecol Oncol, Zhenjiang, Jiangsu, Peoples R China. 7.[6]Zibo Cent Hosp, Ctr Translat Med, Zibo, Peoples R China. 8.[7]Zibo Cent Hosp, Ctr Translat Med, Zibo, Peoples R China. 9.[8]Zibo Cent Hosp, Ctr Translat Med, Zibo, Peoples R China. 10.[9]Zibo Cent Hosp, Ctr Translat Med, Zibo, Peoples R China. |
推荐引用方式 GB/T 7714 | Zhao, Peiqing[1],Wang, Sujie[2],Jiang, Jie[3],et al. TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1-NF-kappa B and - AP-1 pathways[J]. MOLECULAR IMMUNOLOGY,2018,101:471-478. |
APA | Zhao, Peiqing[1].,Wang, Sujie[2].,Jiang, Jie[3].,Liu, Hong[4].,Zhu, Xiaolan[5].,...&Xu, Wenlin[12].(2018).TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1-NF-kappa B and - AP-1 pathways.MOLECULAR IMMUNOLOGY,101,471-478. |
MLA | Zhao, Peiqing[1],et al."TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1-NF-kappa B and - AP-1 pathways".MOLECULAR IMMUNOLOGY 101(2018):471-478. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论